BIOGEN INC. Line of Credit Facility, Maximum Borrowing Capacity
BIOGEN INC. (BIIB) had Line of Credit Facility, Maximum Borrowing Capacity of $1.00 billion as of 2015-12-31, per its 10-K filed 2020-02-06.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2020-02-06
- 2015-12-31: Line of Credit Facility, Maximum Borrowing Capacity $1.00B.
- 2015-09-30: Line of Credit Facility, Maximum Borrowing Capacity $1.00B.
- 2014-03-31: Line of Credit Facility, Maximum Borrowing Capacity $750.00M.
- 2013-12-31: Line of Credit Facility, Maximum Borrowing Capacity $750.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2015-12-31 | $1.00B 10-K · filed 2020-02-06 |
| 2015-09-30 | $1.00B 10-Q · filed 2015-10-21 |
| 2014-03-31 | $750.00M 10-Q · filed 2014-10-22 |
| 2013-12-31 | $750.00M 10-K · filed 2016-02-03 |
| 2013-09-30 | $750.00M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $750.00M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $750.00M 10-K · filed 2015-02-04 |
| 2012-12-31 | $360.00M 10-K · filed 2013-02-05 |
| 2012-09-30 | $360.00M 10-Q · filed 2012-10-25 |
| 2012-06-30 | $360.00M 10-Q · filed 2012-07-24 |
| 2011-12-31 | $360.00M 10-K · filed 2012-02-03 |
| 2010-12-31 | $360.00M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |